Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06699849 · ClinicalTrials.gov registry record · Phase 2
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
A Phase 2 study of Sickle Cell Disease Vaso-occlusive Crisis, sponsored by CSL Behring.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 14
- Study locations
NCT06699849: Recruiting Phase 2 study of Sickle Cell Disease Vaso-occlusive Crisis, sponsored by CSL Behring.
NCT06699849 is a Phase 2 study of Sickle Cell Disease Vaso-occlusive Crisis that is actively recruiting participants, run by CSL Behring. The registered enrollment target is 70 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower). The trial reports 14 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06699849, a Phase 2 study of Sickle Cell Disease Vaso-occlusive Crisis, is actively recruiting participants, sponsored by CSL Behring.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 14
- Study locations
Study Summary
This is a phase 2, randomized, multiple-dose, placebo-controlled study designed to evaluate the safety, efficacy, and pharmacokinetics (PK) of CSL889 (human hemopexin) when given intravenously (IV) to adults and adolescents with sickle cell disease (SCD) experiencing vaso-occlusive crises (VOC). The main objectives of the study are to evaluate the safety and tolerability of CSL889 in study participants, and to assess how CSL889 affects the time it takes for VOC to resolve in participants with SCD.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL CSL889
Study Locations (14)
New York
- Mount Sinai Medical Center - New York
- Jacobi Medical Center - The Bronx
- Albert Einstein College of Medicine - The Bronx
Other
- Hacettepe Universitesi - Ankara
- Istanbul Universitesi - Istanbul
- Özel Acibadem Adana Hastanesi - Seyhan
Florida
- Golisano Children's Hospital - Fort Myers
- The Foundation for Sickle Cell Disease - Hollywood
Ohio
- University of Cincinnati - Cincinnati
- The Ohio State University - Columbus
California
- University of California Irvine - Orange
Maryland
- University of Maryland - Baltimore
Michigan
- Henry Ford Health System - Detroit
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-07-10 |
| Est. Completion | 2027-08-07 |
| Phase | Phase 2 |
What NCT06699849 shows while recruiting
NCT06699849 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Sickle Cell Disease Vaso-occlusive Crisis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06699849 lists 14 locations in 8 states (New York, Other, Florida).
Frequently Asked Questions
What is clinical trial NCT06699849 about?
NCT06699849 is a clinical study titled "Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis". This is a phase 2, randomized, multiple-dose, placebo-controlled study designed to evaluate the safety, efficacy, and pharmacokinetics (PK) of CSL889 (human hemopexin) when given intravenously (IV) to adults and adolescents with sickle cell disease (SCD) experiencing vaso-occlusive crises (VOC). The...
What is the current status of trial NCT06699849?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2025-07-10. Estimated completion is 2027-08-07.
What conditions does trial NCT06699849 study?
This clinical trial studies the following conditions: Sickle Cell Disease Vaso-occlusive Crisis.
What interventions are being tested in trial NCT06699849?
The interventions under investigation include: Placebo (DRUG), CSL889 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06699849?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06699849 being conducted?
This trial has 14 study locations across California, Florida, Maryland, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06699849's enrollment target sits among peer trials
70 937th of 2000 higher than 1,037 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI